Want to see DLHC full AI Analyst Report?
DLHC Stock Chart & Stats
$6.36
$0.05(0.65%)
At close: 4:00 PM EST
$6.36
$0.05(0.65%)
Day’s Range― - ―
52-Week Range$5.12 - $8.10
Previous CloseN/A
Volume6.05K
Average Volume (3M)27.65K
Market Cap
$76.23M
Enterprise Value$225.16M
Total Cash (Recent Filing)$131.00K
Total Debt (Recent Filing)$145.58M
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Aug 05, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding14,493,035
10 Day Avg. Volume37,306
30 Day Avg. Volume27,646
Financial Highlights & Ratios
PEG Ratio-0.73
Price to Book (P/B)0.72
Price to Sales (P/S)0.24
P/FCF Ratio3.54
Enterprise Value/Market Cap2.95
Enterprise Value/Revenue0.77
Enterprise Value/Gross Profit4.53
Enterprise Value/Ebitda9.80
Forecast
1Y Price Target
$10.00Price Target Upside57.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.46
Revenue Forecast (FY)$234.89M
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationConsistent positive operating and free cash flow provides durable liquidity to fund operations, service debt, and invest in bids. Even with revenue pressure, FCF near operating cash flow supports deleveraging and reduces refinancing risk over the next several quarters.
Margin ResilienceSustained adjusted EBITDA margins indicate the company can preserve profitability through cost scaling and right‑sizing. Durable margin control helps absorb revenue volatility in federal services and supports cash conversion and covenant compliance while pursuing contract wins.
Contract Visibility & PipelineA sole‑source NIH extension and improving bid pipeline materially increase near‑term revenue visibility and provide runway to rebuild scale. Combined with noted award flow, this structural revenue backstop supports steadier utilization and revenue recovery over coming contract cycles.
Bears Say
Declining Revenue And Net LossesSustained revenue contraction and a return to net losses weaken earnings power and reduce retained earnings available for reinvestment. If top‑line trends persist, margin recovery and cash conversion could be constrained, limiting long‑term growth and deleveraging progress.
Elevated LeverageMaterial leverage, even after some reduction, limits financial flexibility and increases sensitivity to contract timing or margin pressure. High funded debt relative to equity constrains investment capacity and makes covenant management and refinancing more challenging over the medium term.
Structural Contract LossesLoss of long‑standing programs to small business set‑asides represents a structural shrinkage of revenue base rather than a temporary dip. Replacing durable, high‑margin government work requires winning new recompetes or adjacent awards, lengthening recovery time and increasing bid dependency.
DLH Holdings News
DLHC FAQ
What was DLH Holdings’s price range in the past 12 months?
DLH Holdings lowest stock price was $5.12 and its highest was $8.10 in the past 12 months.
What is DLH Holdings’s market cap?
DLH Holdings’s market cap is $76.23M.
When is DLH Holdings’s upcoming earnings report date?
DLH Holdings’s upcoming earnings report date is Aug 05, 2026 which is in 30 days.
How were DLH Holdings’s earnings last quarter?
DLH Holdings released its earnings results on May 06, 2026. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.16 by -$0.01.
Is DLH Holdings overvalued?
According to Wall Street analysts DLH Holdings’s price is currently Undervalued.
Does DLH Holdings pay dividends?
DLH Holdings does not currently pay dividends.
What is DLH Holdings’s EPS estimate?
DLH Holdings’s EPS estimate is -0.17.
How many shares outstanding does DLH Holdings have?
DLH Holdings has 14,493,035 shares outstanding.
What happened to DLH Holdings’s price movement after its last earnings report?
DLH Holdings reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.16. Following the earnings report the stock price went up 2.321%.
Which hedge fund is a major shareholder of DLH Holdings?
Currently, no hedge funds are holding shares in DLHC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
DLH Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (57.23% Upside)
$10.00 (57.23% Upside)
Insider Transactions
Bought Shares
Worth $757.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-26.72%
12-Months-Change
Fundamentals
Return on Equity
-4.00%
Trailing 12-Months
Asset Growth
-9.75%
Trailing 12-Months
Company Description
DLH Holdings
DLH Holdings Corp., headquartered in Atlanta, Georgia, was established in 1969 and operated as TeamStaff, Inc. until its name change in June 2012. The company specializes in offering a range of technology-enabled business process outsourcing, comprehensive program management solutions, and public health research and analytics services throughout the United States, with a primary focus on the federal health services market. A significant portion of DLH's work involves defense and veterans' health, where it delivers integrated healthcare, technology, and logistical support. Key clients in this sector include the Department of Veterans Affairs (VA), the Defense Health Agency, the Tele-medicine and Advanced Technology Research Center, the Navy Bureau of Medicine and Surgery, and the Army Medical Research and Material Command. Additionally, the company provides diverse human services and solutions, covering areas such as rigorous monitoring and evaluation, efficient electronic medical records migration, robust data collection and management, and thorough nutritional and social health assessments. It also offers expert IT system architecture design, strategic migration planning, and continuous maintenance services. In the sphere of public health and life sciences, DLH undertakes crucial initiatives like clinical trials, epidemiological studies, and disease prevention. It actively promotes health among underserved and at-risk communities through the creation of impactful strategic communication campaigns, research into emerging health trends, in-depth health informatics analyses, and the application of proven best practices.
DLHC Company Deck
DLHC Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call communicated a mixed picture: material near-term financial headwinds with a steep year-over-year revenue decline (~33.5%) and a sharp drop in adjusted EBITDA (~43.6%), largely driven by program transitions to small business set-asides and contract completions. Offsetting these negatives, management reported margin resilience (9% adjusted EBITDA margin), positive free cash flow (~$3.8M), resumed deleveraging (debt reduced to $132.7M), a two-year NIH contract extension adding revenue visibility, recognition for technology capabilities, and an improving pipeline as delayed procurements return to market. Risks remain around federal health reprioritization and typical government procurement timing uncertainty, but the company appears to be stabilizing its cost structure and positioning for upcoming opportunities.View all DLHC earnings summariesDLHC Stock 12 Month Forecast
Average Price Target
$10.00
▲(57.23% Upside)
Technical Analysis
Ownership Overview
35.51% Insiders
7.37% Mutual Funds
26.87% Other Institutional Investors
26.51% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---